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ORIGINAL ARTICLE
In 2002, the World Health Organization (WHO)
estimated 8.8 million new cases of tuberculosis
(TB) worldwide, with an incidence rate of 141 per
100,000 population, and 1.8 million deaths due
to TB.1 TB continues to pose a heavy public health
burden in Taiwan despite rich medical resources
and almost universal coverage of all people by the
National Health Insurance program since 1995.
The WHO introduced a five-element strategy of
directly observed therapy short-course (DOTS)
as the standard of care of pulmonary TB.2,3 As
fTaiwan is not a member of the WHO, most o
the population are not covered by this project.
However, for countries with adequate health in-
rfrastructure and sufficient economic resources fo
TB control, adopting other management modali-
ties in addition to the DOTS strategy may provide
further benefit.4
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Background/Purpose: Tuberculosis (TB) continues to pose a heavy public health burden in Taiwan. This
prospective study analyzed the factors influencing treatment outcome in patients with TB treated with and
without a hospital-based case management (HBCM) approach in a referral center in Taipei.
Methods: A register-based cohort study design was used to enroll all new cases of pulmonary or extra-
g pulmonary TB from February 2003 to January 2004. The case manager served as the coordinator amon
tpatients, physicians and public health nurses, to facilitate compliance with anti-TB treatment. Treatmen
outcomes were assessed according to the consensus recommendations of the World Health Organization
and the International Union Against Tuberculosis and Lung Disease.
Results: rSuspected or confirmed pulmonary or extrapulmonary TB was diagnosed in 524 patients in ou
hospital from February 2003 to January 2004. Fifty-two of these patients were excluded due to duplicate
reporting, previous treatment or death before enrollment. Out of 472 patients enrolled, 103 whose origi-
nal diagnosis was revised were further excluded, leaving 369 cases eligible for analysis. Patients with case
management had a significantly higher rate of successful treatment (cured plus completed treatment)
compared to patients without case management, (240/277, 86.6% vs. 67/92, 72.8%; p = 0.002). The over-
all successful treatment rate including both case and non-case management was 83.2% (307/369), which
was higher than the nationwide surveillance data of 78.3% in 2002 and 69.4% in 2003.
Conclusion: Treatment of TB patients by a HBCM approach provides improved treatment outcomes
compared to those without case management. [J Formos Med Assoc 2006;105(8):636–644]
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Nonadherence to treatment is one of the
major causes of treatment failure and the emer-
gence of drug-resistant TB, and is the most serious
problem in the control of TB in Taiwan. The strat-
egy of TB control should be modified according 
to local epidemiology, specific socioeconomic and
cultural circumstances, and the type of healthcare
program. Although a previous study in Taiwan
found that case notification of TB was quite com-
plete, and reported patients were followed up by
public health nurses, compliance with anti-TB
treatment remains unsatisfactory.5 Public health
nurses who serve as government employees at
local health units are assigned the responsibility
of following up compliance to anti-TB treatment.
However, due to poor communication with physi-
cians, they are usually unaware of patients’ actual
clinical condition and, hence, not fully trusted by
patients. Health education for patients about the
disease was also insufficient. We tried to address
these problems by employing a hospital-based
case management (HBCM) approach for the con-
trol of TB. Treatment outcomes were compared
between patients with and without case manage-
ment and with nationwide surveillance data. Part
of the results of this study has been previously
presented in the form of an abstract.6
Methods
Study patients
In Taiwan, suspected or confirmed diagnosis of TB,
including pulmonary and extrapulmonary cases,
requires notification under government regula-
tions and registration of the case both in the data-
base of the reporting hospital and in the Center
for Disease Control in Taiwan.7 In this study, all
patients reported from February 2003 to January
2004 in our hospital were assigned to receive case
management except for those with a duplicate
report, previous treatment or death prior to the
enrollment period. If the diagnosis was revised
after enrollment, either due to nontuberculous
mycobacterial (NTM) growth in culture or to
diagnosis of other lung diseases, then the anti-TB
regimen was discontinued and the patient with-
drawn from the HBCM program. If patients
changed their healthcare providers, the case man-
ager then pro cvided clinical information to publi
health nurses for further follow-up, but these pa-
tients were no longer participants in our HBCM
program (Figure 1).
Case definition and diagnostic categories
The standard WHO case definition for TB1 with
modifications was adopted, requiring bacterio-
ylogic or pathologic confirmation, or diagnosis b
a clinician. A smear-positive pulmonary case was
defined as the finding of at least two initial spu-
tum acid-fast bacilli smear positive (AFB+ r); o
one sputum AFB+ and radiographic abnormali-
ties consistent with active pulmonary TB as
determined by a clinician; or one sputum AFB+
and culture positive for Mycobacterium tuberculosis.
yA smear-negative, culture-positive pulmonar
rcase was defined based on a positive culture fo
M. tuberculosis but negative AFB sputum exam-
inations, and radiographic abnormalities consis-
tent with active pulmonary TB. A smear-negative,
culture-negative pulmonary case was defined as
a negative sputum AFB and culture for M. tubercu-
losis, or a patient whose sputum was not available
for examination; radiographic abnormalities
consistent with active pulmonary TB; and deci-
fsion by a clinician to treat with a full course o
anti-TB therapy. An extrapulmonary case was de-
fined as a patient with TB of organs other than
the lungs, proved either histologically or bacteri-
ologically. A patient with both pulmonary and
extrapulmonary TB diagnoses was classified as a
pulmonary case.
Case management
A team of personnel was assigned the responsi-
bility for continuity of care, patient follow-up,
health education and reassessment. As shown in
Figure 2, the HBCM approach for TB control re-
quired four types of healthcare providers in the
following roles: (1) the treating physician who re-
gported the cases and/or was responsible for treatin
ypatients; (2) the managing physician, a pulmonar
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specialist who provided the case manager with
consultation for any required information regard-
ing the diagnosis and/or treatment of patients;
(3) public health nurses who were government
employees and served at the local health unit 
located at the corresponding patient’s residence;
(4) the case manager who served in the hos-
pital in the following capacities: (a) coordinated
between physicians, public health nurses and
patients for better understanding of patients’
clinical conditions; (b) offered health education
to patients and their family members once the
diagnosis was initially made; (c) contacted pa-
tients regularly to ensure compliance to treat-
ment; (d) monitored the anti-TB drugs’ side
effects by telephone contact; (e) tracked for fail-
ure to keep appointments; (f) monitored the
y appropriateness of the anti-TB regimen b
reviewing medical records.
Treatment outcomes
The definitions of the consensus-based recom-
 mendations developed by the working group
of the WHO and the International tUnion Agains
Tuberculosis and Lung Disease (IUATLD) on uni-
form reporting of TB treatment outcomes1,8 were
adopted in this study and are briefly summarized. 
Cure was defined as completion of a full course
rof anti-TB therapy in an initially smear- and/o
culture-positive patient who was smear-negative
in the last month of treatment; treatment com-
tpleted was defined as completion of treatmen
rbut in a patient who did not meet the criteria fo
cure or failure; death was defined as a patient who
tdied from any reason during treatment; treatmen
89 excluded due to change of
diagnosis (NTM 47, Others 42)
14 excluded due to change of
diagnosis (NTM 14, Others 0)
366 treated in the study
hospital with case management
106 treated by other healthcare













All cases reported by the hospital, including
pulmonary and extrapulmonary cases (n = 524)
52 excluded due to duplicate report, previous
treatment, or death before enrollment (n = 472)
iF gure 1. Study population and treatment 
outcomes. A total of 524 patients with suspected or
confirmed pulmonary or extrapulmonary tuberculo-
sis were reported to the Center for Disease Control.
After exclusion of patients with duplicate reports,
previous treatment, or death, the remaining 472 
patients were enrolled. Among these patients, 366
were treated in the study hospital under case 
management and 106 were treated by other health-
care providers without case management. Patients
whose diagnosis was subsequently changed to
categories including growth of nontuberculous
mycobacteria (NTM) on culture and other lung









iF gure 2. Components and relationships between patients
and personnel involved in case management.
failure was defined as a smear-positive patient
who remained smear-positive at 5 months or
later after the start of treatment; default was de-
fined as treatment interruption for 2 consecutive
months or more; transfer out was defined as
transfer to another reporting unit in a patient for
whom the treatment outcome was not known;
still on treatment was defined as a patient who
remained on treatment at the end of follow-up;
successfully treated was defined as either cured or
completion of treatment; unsuccessfully treated
was defined as a treatment outcome other than
successfully treated.
All patients were followed up to determine
their treatment outcomes 1 year after the last pa-
tient was enrolled. Data on the treatment out-
comes of patients not under HBCM were obtained
from public health nurses and an online central
registry database from the Center for Disease
Control in Taiwan.9
Statistical analysis
All continuous data were expressed as mean ± SD.
Differences in the means of continuous measure-
ments were tested by Student’s t test. χ2 and Fisher’s
exact tests were used for comparison of category
data. A multiple logistic regression model was used
to evaluate whether case management was an in-
dependent predictor of successful treatment after
adjusting for age and gender. A p value < 0.05 was
considered to be statistically significant. All statis-
tical analyses were performed on a personal com-
puter with SPSS version 12.0 (SPSS Inc., Chicago,
IL, USA) for Windows.
Results
Study population and demographic
characteristics
Between February 2003 and January 2004, 524
suspected or confirmed cases of pulmonary or
extrapulmonary TB were reported. Fifty-two of
these cases were excluded due to either duplicate
reporting, previous treatment, initiation of treat-
ment not during the enrollment period or death
before enrollment. Out of 472 patients enrolled,
366 were treated at our hospital under the
HBCM program, and 106 changed their health-
care providers and were not participants in the
case management program (non-HBCM). Patients
whose diagnosis was revised after enrollment,
including 61 with NTM growth on culture and
42 with other lung diseases, were further excluded.
The remaining 369 patients comprised the popu-
lation of this study including 277 participants in
the HBCM program and 92 nonparticipants
(Figure 1).
There were no significant differences in gen-
rder, mean age or percentage of pulmonary o
extrapulmonary cases between patients with and
without HBCM (Table 1). The smear-positive
rate for pulmonary cases was 36.8% (85/231) in
the HBCM group, 29.6% (24/81) in the non-
HBCM group and 34.9% (109/312) in the over-
tall group. Most (75%) of the patients treated a
tour hospital remained under HBCM throughou
the treatment course. Among 92 patients who
changed their healthcare providers, the median
time from enrollment until change was 54 days,
with 62 of them changing within the first month
after enrollment.
Treatment outcomes
yThe rate of successful treatment was significantl
higher in patients with HBCM when compared to
those without HBCM (86.6% vs. 72.8%, p = 0.002)
(Table 2). If the two groups were pooled together,
the percentage of patients with successful treat-
ment in the overall group was 83.2% (307/369).
There was no significant difference in the treat-
ment success rates between pulmonary and ex-
trapulmonary cases (82.1% vs. 89.5%, p = 0.168)
or by gender (males 83.1% vs. females 83.5%,
p = 0.920). Patients with unsuc tcessful treatmen
outcomes had significantly older mean age than
those with successful treatment (mean age,
65.9 ± 20.6 years vs. 51.6 ± 20.1 years, p < 0.001)
(Table 3).
 According to the standardized WHO and
IUATLD recommendations for treatment out-
comes, all deaths during the treatment duration
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irrespective of cause were counted in the anal-
ysis.1,8 Among patients with unsuccessful treat-
ment outcomes, 26 (9.4%) in the HBCM group
and 16 (17.4%) in the non-HBCM group died,
which comprised the majority of patients with
unsuccessful treatment (Table 2). Further anal-
ysis of treatment outcomes excluding all patients
who died showed a significantly higher treat-
ment success rate in the HBCM group when
compared with the non-HBCM group (95.6% vs.
88.2%, p = c0.027) (Table 4). Multiple logisti
tregression analysis of predictors of treatmen
outcome showed that HBCM was the single
t independent predictor of successful treatmen
Table 1. Comparison of demographic characteristics and diagnostic findings of the 369 patients treated
with or without case management
Characteristics With case management (n = 277) Without case management (n = 92) p
Male 179 (64.6%) 57 (62.0%) 0.64
Mean age ± SD (yr) 54.7 ± 20.3 52.0 ± 22.4 0.28
Age distribution (yr)
< 15 2 0
15–39 69 34
40–64 101 22
> 64 105 36
Pulmonary cases 231 (83.4%) 81 (88.0%) 0.28
Smear (+) 85 24
Smear (−), culture (+) 57 29
Smear (−), culture (−) 89 28
Extrapulmonary cases 46 (16.6%) 11 (12.0%)







SD = standard deviation.
Table 2. Comparison of treatment outcomes in patients who received case management (n = 277) and
non-case management (n = 92)
Characteristics Case management, n (%) Non-case management, n (%)
Successfully treated 240 (86.6) 67 (72.8)
Cure 109 (39.4) N/A*
Treatment completed 131 (47.3) 67 (72.8)
Unsuccessfully treated 37 (13.4) 25 (27.2)
Still on treatment 1 (0.4) 3 (3.3)
Treatment failure 0 (0.0) 1 (1.1)
Default 9 (3.2) 2 (2.2)
Transfer out 1 (0.4) 3 (3.3)
Died 26 (9.4) 16 (17.4)
*In non-hospital-based case management patients with successful treatment, follow-up bacteriologic results before treatment completion
were not available to the case manager. Hence, we classified all of these patients’ treatment outcomes as having treatment completed.
N/A = not available.
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either including (relative risk [RR], 2.82; 95%
confidence interval [CI], 1.53–5.19) or excluding
patients who died (RR, 2.77; 95% CI, 1.09–7.02)
(Table 5).
Discussion
This study showed that patients with TB treated
with a HBCM approach had a significantly higher
rate of successful treatment outcome compared
to those without HBCM. Patients who died com-
prised the majority of patients with unsuccessful
treatment outcomes, although the causes of death
in these patients were not necessarily due to TB and
were often difficult to discern due to the presence
of comorbidities. Further analysis of treatment out-
comes after excluding those patients who died still
showed a significantly better treatment outcome 
tin HBCM patients. Deaths during the treatmen
Table 3. Univariate analysis of association of management approach and patient characteristics with
successful treatment outcome including patients who died during treatment
Successfully treated Unsuccessfully treated p
Case management (n = 277), n (%) 240 (86.6) 37 (13.4) 0.002
Non-case management (n = 92), n (%) 67 (72.8) 25 (27.2)
Pulmonary cases (n = 312), n (%) 256 (82.1) 56 (17.9) 0.17
Extrapulmonary cases (n = 57), n (%) 51 (89.5) 6 (10.5)
Male (n = 236), n (%) 196 (83.1) 40 (16.9) 0.92
Female (n = 133), n (%) 111 (83.5) 22 (16.5)
Mean age, mean ± SD (yr) 51.6 ± 20.1 65.9 ± 20.6 < 0.001
SD = standard deviation.
Table 4. Univariate analysis of association of management approach and patient characteristics with
successful treatment outcome excluding patients who died during treatment
Successfully treated Unsuccessfully treated p
Case management (n = 251), n (%) 240 (95.6) 11 (4.4) 0.027
Non-case management (n = 76), n (%) 67 (88.2) 9 (11.8)
Pulmonary cases (n = 272), n (%) 256 (94.1) 16 (5.9) 0.70
Extrapulmonary cases (n = 55), n (%) 51 (92.7) 4 (7.3)
Male (n = 204), n (%) 196 (96.1) 8 (3.9) 0.033
Female (n = 123), n (%) 111 (90.2) 12 (9.8)
Mean age, mean ± SD (yr) 51.6 ± 20.1 45.5 ± 20.3 0.19
SD = standard deviation.
Table 5. Multiple logistic regression of association of case management, gender and age as predictors of
successful treatment outcome including and excluding patients who died during treatment
Outcomes β p Relative risk 95% CI
Including patients who died
Case management 1.035 0.001 2.82 1.53–5.19
Age −0.039 < 0.001 0.96 0.95–0.98
Excluding patients who died
Case management 1.019 0.032 2.77 1.09–7.02
Gender 0.919 0.053 2.51 0.99–6.37
CI = confidence interval.
period were due to delay in diagnosis and/or 
comorbidities rather than due to the treatment. In
the evaluation of treatment outcomes, exclusion of
patients who died might more accurately reflect
the efficacy of a control strategy. This study found
an improved treatment success rate compared with
both the previous data with non-HBCM reported
from the same hospital in 1982–1983 as well as
nationwide surveillance data in 2003.9,10
This study included consecutively reported TB
cases in a single referral center. This cohort had
comparable demographic characteristics to the
nationwide surveillance data including gender
ratio, mean age, rate of open pulmonary TB (smear-
positive plus smear-negative, culture-positive) and
rate of extrapulmonary TB.9 In 1997, the Bureau
of National Health Insurance in Taiwan introduced
the following two policies related to TB notifica-
tion: (1) the no-notification-no-reimbursement
policy, and (2) the notification-fee policy, which
substantially improved completeness of report-
ing.5 In addition, according to the Communi-
cable Disease Control Act in Taiwan, only the
reporting of TB is required but reporting the
change of diagnosis is not required.7 Out of 524
cases reported in our hospital during the study
period, 369 (70.4%) were eventually confirmed
to have either pulmonary or extrapulmonary TB,
a percentage comparable to the nationwide rate
in 2003 (22,362 reported of which 15,042 con-
firmed, 67.3%). Since TB can mimic many other
lung diseases and other lung diseases also mimic
TB, diagnosis presents a challenge. Under the
HBCM approach in this study, once patients were
reported to have TB, public health nurses who
served the health unit located at patients’ resi-
dence began to follow up the patients. However,
it should be noted that under the current system,
public health nurses face many difficulties in con-
tacting the responsible physicians or obtaining
the required clinical information in a timely
manner. Intervention by the case manager is thus
required to help reduce the burden placed on
public health nurses. Studies that show the effect
of such coordinated efforts on treatment out-
comes are required.
In this study, about one-fourth of patients
fchanged their care providers and dropped out o
case management after enrollment. The reasons
 for why patients were not managed at the same
hospital are multifactorial. First, patients are able
to choose care providers freely under the
 National Health Insurance program; second,
patients changed care providers if they moved
f or changed their work; third, the epidemic o
severe acute respiratory syndrome (SARS) occur-
red during the study period and led to the evacua-
rtion of all TB isolation wards in order to care fo
SARS patients. The case manager continued to
follow up those patients who changed care
providers and facilitated continuity of care at the
institution to which these patients were trans-
ferred and by working with public health nurses.
This intensive follow-up explains the overall
successful treatment rate of 83.2%, which is an
improvement when compared to the nationwide
rrate of 78.3% in 2002 and 69.4% in 2003 fo
surveillance data.9
DOTS, an international standard of TB con-
trol, contains five elements: (1) political com-
mitment to support TB treatment; (2) the passive
detection of active TB by sputum microscopy; (3)
ensuring drug supply; (4) standardized record-
ing and reporting system; (5) direct observation
of treatment (ingestion of anti-TB medications
directly supervised by a healthcare worker) dur-
ing at least the first 2 months.2 By combining the
aspects of government regulation, universal health
insurance coverage, and a case management ap-
proach for TB control, the strategy reported in
this study is more comprehensive than DOTS,
except for direct observation of therapy. To achieve
direct observation, patients must either go to the
thealthcare provider or the healthcare worker mus
tvisit them. Implementation of required patien
visits to observe treatment has been challenged
by considerations of patients’ willingness, and
home visits by healthcare workers would require
fenormous resources. Nevertheless, the impact o
not implementing this aspect of DOTS may also
t be great. By the time of completion of the firs
2 months of treatment, most patients will have
R.L. Lin, et al
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clinical improvement and are likely to interrupt
their treatment if direct observation of treatment
is discontinued. The possibility of nonadherence
and interruption if direct observation of treatment
is implemented only during the first 2 months
would thus be far greater. Although the HBCM
approach does not directly observe treatment, it
may be reasonable to assume compliance in most
cases based on the patient’s willingness to treat,
their clinical response, roentgenographic improve-
ment and bacteriologic conversion. The case man-
ager should seek to earn the trust of patients as
this may be more important than just watching
them take the drugs.
A limitation of DOTS is the inadequate atten-
tion to smear-negative cases who can also transmit
the disease.11,12 The broad coverage of the HBCM
approach in this study to all TB patients could
further reduce transmission early after the diag-
nosis. Another drawback of DOTS is patients’ con-
cern about the stigma of TB infection recognized
by their neighbors when healthcare workers visit
them for direct observation of treatment. In con-
trast, the HBCM approach does not infringe on
patients’ right to privacy.
Several randomized control studies suggested
that DOTS may not be better than self-
administered therapy for treatment comple-
tion.13–16 Although no controlled cost-effective
study comparing case management and DOTS
has been reported, data showed that DOTS
would generate cost savings only in settings with
high default and relapse rates.17,18 A case manage-
ment control strategy to cover all TB patients fol-
lowed by selective DOTS for patients with high
risk of nonadherence may be more cost-effective
than DOTS alone. Collaboration of case man-
agers between different healthcare providers,
with sharing of patient information and conti-
nuity of care if patients move or require transfer,
will constitute a network of care that reduces the
default rate.
This study was limited by lack of randomized
group assignment and the inclusion of patients
who changed to various healthcare providers. It
is difficult to conduct such a randomized control
study under the infrastructure of an open system
health insurance program. In conclusion, this
study supports that HBCM results in improved
treatment outcomes in newly diagnosed patients
with pulmonary or extrapulmonary TB.
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